Compass Pathways is trading 5.65% down at $11.05 amid a broader market rotation away from high-beta biotech names and general Nasdaq weakness.
- The move follows a sharp morning selloff despite a lack of company-specific announcements, earnings updates, or regulatory events.
- Investors appear to be shifting toward a risk-off sentiment, impacting speculative healthcare and developmental-stage stocks.
- No direct catalysts were identified in recent search results to explain the specific downward trajectory.